Proteome delivers encouraging results from Alzheimers study

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function.

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function.

The firm said the results provide important in-vivo proof of principle and demonstrate the efficacy of its compounds.

The next phase, which will start immediately in January, is to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues.

Christopher Pearce, Chief Executive Officer, said: "Our goal was to deliver in-vivo proof of principle for CK1D in Alzheimer's disease. We are delighted that this has been successfully achieved in 2012.

"These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer's.

"In light of UK government's recent commitment to fully fund NHS access to novel treatments for AD, we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers. We will continue to push our CK1D programme forward and will actively engage with the pharmaceutical industry to bring our compounds to clinical trials as soon as possible".

The share price rose 1.19% to 64p by 11:00.

NR

Recommended

Three dividend stocks from the dynamic Asia/Pacific region
Share tips

Three dividend stocks from the dynamic Asia/Pacific region

Professional investor Sat Duhra of the Henderson Far East Income investment trust highlights three of his favourite stocks.
18 Oct 2021
Share tips of the week – 15 October
Share tips

Share tips of the week – 15 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
15 Oct 2021
Trading: stash the family cash in this cheap wealth management firm
Trading

Trading: stash the family cash in this cheap wealth management firm

Wealth management is a growth market. Rathbone Brothers should be a prime beneficiary – and looks cheap. Matthew Partridge explains the best way to pl…
12 Oct 2021
What the best-performing investment trusts of the past 20 years can teach us
Investment trusts

What the best-performing investment trusts of the past 20 years can teach us

Forty-two trusts have risen more than tenfold over the last two decades. What made the winners stand out? And how can we identify future outperformers…
12 Oct 2021

Most Popular

How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
How to invest in SMRs – the future of green energy
Energy

How to invest in SMRs – the future of green energy

The UK’s electricity supply needs to be more robust for days when the wind doesn’t blow. We need nuclear power, says Dominic Frisby. And the future of…
6 Oct 2021
Why the world’s most important economic data release has unnerved markets
US Economy

Why the world’s most important economic data release has unnerved markets

The US added only 194,000 jobs in September, far shorter than the 500,000 that were expected. John Stepek explains why markets didn't react as they no…
11 Oct 2021